全文获取类型
收费全文 | 3836篇 |
免费 | 254篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 135篇 |
妇产科学 | 51篇 |
基础医学 | 561篇 |
口腔科学 | 107篇 |
临床医学 | 238篇 |
内科学 | 946篇 |
皮肤病学 | 101篇 |
神经病学 | 347篇 |
特种医学 | 173篇 |
外科学 | 467篇 |
综合类 | 10篇 |
预防医学 | 142篇 |
眼科学 | 73篇 |
药学 | 291篇 |
中国医学 | 8篇 |
肿瘤学 | 422篇 |
出版年
2023年 | 29篇 |
2022年 | 43篇 |
2021年 | 109篇 |
2020年 | 79篇 |
2019年 | 102篇 |
2018年 | 120篇 |
2017年 | 99篇 |
2016年 | 105篇 |
2015年 | 99篇 |
2014年 | 147篇 |
2013年 | 152篇 |
2012年 | 300篇 |
2011年 | 280篇 |
2010年 | 159篇 |
2009年 | 117篇 |
2008年 | 221篇 |
2007年 | 219篇 |
2006年 | 175篇 |
2005年 | 203篇 |
2004年 | 175篇 |
2003年 | 183篇 |
2002年 | 165篇 |
2001年 | 56篇 |
2000年 | 48篇 |
1999年 | 71篇 |
1998年 | 30篇 |
1997年 | 32篇 |
1996年 | 20篇 |
1995年 | 21篇 |
1994年 | 20篇 |
1993年 | 19篇 |
1992年 | 50篇 |
1991年 | 41篇 |
1990年 | 28篇 |
1989年 | 55篇 |
1988年 | 37篇 |
1987年 | 44篇 |
1986年 | 43篇 |
1985年 | 39篇 |
1984年 | 42篇 |
1983年 | 24篇 |
1982年 | 10篇 |
1981年 | 7篇 |
1980年 | 9篇 |
1979年 | 17篇 |
1978年 | 7篇 |
1977年 | 11篇 |
1976年 | 11篇 |
1972年 | 5篇 |
1966年 | 6篇 |
排序方式: 共有4108条查询结果,搜索用时 15 毫秒
61.
Daniele Santetti Maria Inês de Albuquerque Wilasco Cristina Toscani Leal Dornelles Isabel Cristina Ribas Werlang Fernanda Urruth Fontella Carlos Oscar Kieling Jorge Luiz dos Santos Sandra Maria Gon?alves Vieira Helena Ayako Sueno Goldani 《World journal of gastroenterology : WJG》2015,21(29):8927-8934
AIM: To evaluate the nutritional status and its association with proinflammatory cytokines in children with chronic liver disease.METHODS: We performed a cross-sectional study with 43 children and adolescents, aged 0 to 17 years, diagnosed with chronic liver disease. All patients regularly attended the Pediatric Hepatology Unit and were under nutritional follow up. The exclusion criteria were fever from any etiology at the time of enrollment, inborn errors of the metabolism and any chronic illness. The severity of liver disease was assessed by Child-Pugh, Model for End-stage Liver Disease(MELD) and Pediatric End Stage Liver Disease(PELD) scores. Anthropometric parameters were height/age, body mass index/age and triceps skinfold/age according to World Health Organization standards. The cutoff points for nutritional status were risk of malnutrition(Z-score -1.00) and malnutrition(Z-score -2.00). Interleukin-1β(IL-1β), IL-6 and tumor necrosis factor-α levels were assessed by commercial ELISA kits. For multivariate analysis, linear regression was applied to assess the association between cytokine levels, disease severity and nutritional status. RESULTS: The median(25th-75 th centile) age of the study population was 60(17-116)-mo-old, and 53.5% were female. Biliary atresia was the main cause of chronic liver disease(72%). With respect to Child-Pugh score, cirrhotic patients were distributed as follows: 57.1% Child-Pugh A, a mild presentation of the disease, 34.3% Child-Pugh B, a moderate stage of cirrhosis and 8.6% Child-Pugh C, were considered severe cases. PELD and MELD scores were only above the cutoff point in 5 cases. IL-6 values were increased in patients at nutritional risk(34.9%) compared with those who were well-nourished [7.12(0.58-34.23) pg/m L vs 1.63(0.53-3.43) pg/m L; P = 0.02], correlating inversely with triceps skinfold-for-age z-score(rs =-0.61; P 0.001). IL-6 levels were associated with liver disease severity assessed by Child-Pugh score(P = 0.001). This association remained significant after adjusting for nutritional status in a linear regression model. CONCLUSION: High IL-6 levels were found in children with chronic liver disease at nutritional risk. Inflammatory activity may be related to nutritional status deterioration in these patients. 相似文献
62.
63.
64.
Homeostasis of the hematopoietic system has its roots in the maintenance of hematopoietic stem cells (HSCs) in the bone marrow (BM). HSCs change both phenotypically and functionally with physiological age. The alterations noted in aged HSCs are thought to be a consequence of both cell-intrinsic and extrinsic changes. We review here the age-related changes that the BM microenvironment exerts on HSCs. 相似文献
65.
Fumitake ONO Shinichiro YASUMOTO Minao FURUMURA Takahiro HAMADA Norito ISHII Takashi GYOTOKU Mitsunari HIGUCHI Kenichiro INOKUCHI Kazuo JYO Hideaki KOGA Ayako KOMAI Koji MARUTA Tami MASHIKO Tsukasa MIHARA Hiroko MIYAHARA Minoru MIYASATO Koichiro MUTO Koichi NAGASE Masakazu NAGATA Hideki SAKIHAMA Tomoko TANAHASHI Atsuto UEDA Kyoko YAMAKAWA Chika OHATA Teruki DAINICHI Daisuke TSURUTA Takashi HASHIMOTO 《The Journal of dermatology》2012,39(11):902-908
Famciclovir is a guanine analog antiviral drug used commonly for herpes zoster. Efficacy of famciclovir treatment has been reported to be comparable to valacyclovir treatment. Both of these medications reduce the time to complete cessation of zoster‐associated pain including post‐herpetic neuralgia, as compared to acyclovir. We conducted a multicenter, randomized, open clinical trial in order to evaluate the extent of pain relief afforded by these two antiviral drugs during the acute disease phase of herpes zoster. The study group comprised 86 immunocompetent adult patients suffering from herpes zoster, who were treated with either famciclovir or valacyclovir for 7 days. Of these, 55 patients enrolled in this study within 72 h of the onset of the rash and 31 patients after 72 h of the onset. There was a significant reduction in acute herpes zoster pain with famciclovir on day 7 and at 2–3 weeks in both of these patient groups, while with valacyclovir, there was not significant reduction in pain on day 7. Of patients aged 50 years or older, there was a significantly earlier reduction in pain with famciclovir than with valacyclovir. In addition, a significant reduction in the number of patients with pain was observed as early as days 3–4 with famciclovir treatment as compared with valacyclovir treatment. We conclude that famciclovir was superior to valacyclovir in the relief of acute pain of herpes zoster. Accordingly, famciclovir is recommended for herpes zoster patients with moderate symptoms and a visual analog scale score of under 50 mm. 相似文献
66.
67.
Daisuke Miyaki Hiroshi Aikata Hiromi Kan Hatsue Fujino Ayako Urabe Keiichi Masaki Takayuki Fukuhara Tomoki Kobayashi Noriaki Naeshiro Takashi Nakahara Tomokazu Kawaoka Akira Hiramatsu Shoichi Takahashi Masaki Ishikawa Hideaki Kakizawa Kazuo Awai Kazuaki Chayama 《Journal of gastroenterology and hepatology》2013,28(12):1834-1841
68.
69.
Manabu Hayama Hidekazu Suzuki Takayuki Shiroyama Motohiro Tamiya Norio Okamoto Ayako Tanaka Naoko Morishita Takuji Nishida Takashi Nishihara Tomonori Hirashima 《Journal of thoracic disease》2016,8(1):116-123
Background
Long-term oxygen therapy (LTOT) is sometimes prescribed for patients with advanced lung cancer who are potential candidates for chemotherapy. The aim of this study was to assess the usefulness of chemotherapy for patients with this disease who require LTOT.Methods
The medical records of 40 patients with advanced lung cancer who received LTOT while undergoing systemic chemotherapy at our institution between January 2009 and December 2014 were retrospectively reviewed. Chemotherapy consisted of cytotoxic or molecular-targeted agents.Results
Twenty-four patients had adenocarcinoma, 6 had squamous cell carcinoma, and 10 had small cell lung cancer (SCLC). The median survival time from the date of the first chemotherapy cycle performed in conjunction with LTOT was 194 days. In a multivariate analysis, the only factor significantly associated with better prognosis was the line (first or second) of the first chemotherapy with LTOT (hazard ratio =0.42; 95% confidence interval, 0.18 to 0.94). Among the 40 patients, 10 (25%) received chemotherapy during the last 30 days of their lives, 2 of whom died of chemotherapy-related adverse events.Conclusions
Chemotherapy for patients with advanced lung cancer who receive LTOT may be acceptable if it is the first- or second-line treatment. However, we should be mindful of the potential overuse of chemotherapy and its negative impact on quality of life. 相似文献70.
Yao EH Fukuda N Ueno T Matsuda H Matsumoto K Nagase H Matsumoto Y Takasaka A Serie K Sugiyama H Sawamura T 《Hypertension》2008,52(1):86-92
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a membrane protein that can support the binding, internalization, and proteolytic degradation of oxidized low-density lipoprotein. The LOX-1 expression increases in the neointima after balloon injury. To develop an efficient compound to inhibit LOX-1, we designed and synthesized a novel gene silencer pyrrole-imidazole (PI) polyamide targeting the rat LOX-1 gene promoter (PI polyamide to LOX-1) to the activator protein-1 binding site. We examined the effects of PI polyamide to LOX-1 on the LOX-1 promoter activity, the expression of LOX-1 mRNA and protein, and neointimal hyperplasia of the rat carotid artery after balloon injury. PI polyamide to LOX-1 significantly inhibited the rat LOX-1 promoter activity and decreased the expression of LOX-1 mRNA and protein. After balloon injury of the arteries, PI polyamide to LOX-1 was incubated for 10 minutes. Fluorescein isothiocyanate-labeled PI polyamide was distributed to almost all of the nuclei in the injured artery. PI polyamide to LOX-1 (100 microg) significantly inhibited the neointimal thickening by 58%. PI polyamide preserved the re-endothelialization in the injured artery. PI polyamide significantly inhibited the expression of LOX-1, monocyte chemoattractant protein-1, intercellular adhesion molecule-1, and matrix metalloproteinase-9 mRNAs in the injured artery. The synthetic PI polyamide to LOX-1 decreased the expression of LOX-1 and inhibited neointimal hyperplasia after arterial injury. This novel gene silencer PI polyamide to LOX-1 is, therefore, considered to be a feasible agent for the treatment of in-stent restenosis. 相似文献